This study does not compare FAP expression with CCA genetic mutations or molecular alterations such as clinically relevant, targetable mutations in isocitrate dehydrogenase-1 mutations or fibroblast growth factor receptor-2 fusions or immunotherapy-related indicators such as PD-L1 expression and effector T cell infiltration (46, 47). This evidence concerns the gene FAP and cholangiocarcinoma.